新京报讯（记者王卡拉）在近日召开的2025年补体日大会上，超10个国家的近300位中外顶级专家汇 聚，聚焦血液、肾科、神经三大领域，围绕阵发性睡眠性血红蛋白尿症（PNH）、非典型溶血性尿毒症 综合征（aHUS）、全身型重症肌无力（gMG）、视神经脊髓炎谱系病（NMOSD）四大罕见病，从基 础研究、临床实践到多学科协作展开深度交流。 补体系统是人体先天免疫的核心组成部分，如同维系免疫平衡的"双刃剑"。它在免疫监视与组织稳态中 发挥关键作用，能协助机体清除病原体与受损细胞，守护健康；但当补体系统出现缺陷、功能障碍或过 度活化时，又会成为多种炎性或自身免疫性疾病的驱动因素，诱发PNH、aHUS、gMG、NMOSD等罕 见病。 这类与补体系统相关的罕见病，危害具有显著共性：起病隐匿且临床表现复杂，基层医疗机构认知不 足，导致漏诊、误诊率较高，许多患者需经历漫长的诊断历程；病情进展迅猛且凶险，可累及血液、肾 脏、神经等多个器官系统，严重影响患者生命质量与生存期，给患者家庭带来沉重的身心压力与经济负 担。 PNH的血管内溶血、aHUS的肾脏损伤、gMG导致的肌肉无力、NMOSD高复发高致残——这些曾让临 床束手无策的难题 ...

JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated July 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed below the minimum $1.00 pe ...